-
Product Name
Pembrolizumab (Synonyms: LAMBROLIZUMAB)
- Documents
-
Description
Anti-PDCD1 / PD-1 / CD279 Antibody (Pembrolizumab)
-
Tested applications
ELISA
-
Species reactivity
Human PDCD1 / PD-1 / CD279
-
Alternative names
LAMBROLIZUMAB antibody
-
Isotype
IgG4SP
-
Preparation
Recombinant expression and purified from CHO cells.
-
Clonality
Monoclonal
-
Formulation
0.1 M Pro-Ac, 20 mM Arg, pH 5.0
-
Storage instructions
-80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.
-
Validations
SDS-PAGE
Anti-PDCD1 / PD-1 / CD279 Antibody (pembrolizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
SEC-HPLC
The purity of Anti-PDCD1 / PD-1 / CD279 Antibody (pembrolizumab) is more than 95%, determined by SEC-HPLC.
Bioactivity: ELISA
Immobilized human PD-1 His at 2 ug/mL can bind Anti-PDCD1 / PD-1 / CD279 Antibody (pembrolizumab), EC50=0.0039 ug/mL.
Research in vivo
Pembrolizumab inhibited the tumor growth of MC38 on human PD-1 mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 44.0% at 0.18 mpk at D37.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"